Data Year:

For its 2024 fiscal year, XENCOR INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Bassil I. Dahiyat Ph.D.
President, Chief Executive Officer and Director
Total Compensation $6,811,829 View details Pay Rank By Title In Biotechnology industry #190 View more
John R. Desjarlais Ph.D.
Chief Scientific Officer
Total Compensation $2,827,992 View details Pay Rank By Title In Biotechnology industry #26 View more
John J. Kuch
Former Chief Financial Officer
Total Compensation $4,287,528 View details Pay Rank By Title In Biotechnology industry #75 View more
Celia E. Eckert
General Counsel
Total Compensation $1,971,889 View details Pay Rank By Title In Biotechnology industry #34 View more
Nancy K. Valente M.D.
Chief Development Officer
Total Compensation $2,867,773 View details Pay Rank By Title In Biotechnology industry #114 View more
Bart Jan Cornelissen
Chief Financial Officer
Total Compensation $3,731,011 View details Pay Rank By Title In Biotechnology industry #111 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at XENCOR INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. XENCOR INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. XENCOR INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Bassil I. Dahiyat Ph.D.
President, Chief Executive Officer and Director
Total Cash $1,153,900 Equity $5,649,682 Other $8,247 $6,811,829
John R. Desjarlais Ph.D.
Chief Scientific Officer
Total Cash $801,750 Equity $2,016,995 Other $9,247 $2,827,992
John J. Kuch
Former Chief Financial Officer
Total Cash $143,591 Equity $3,503,758 Other $640,179 $4,287,528
Celia E. Eckert
General Counsel
Total Cash $688,750 Equity $1,273,892 Other $9,247 $1,971,889
Nancy K. Valente M.D.
Chief Development Officer
Total Cash $834,300 Equity $1,910,848 Other $122,625 $2,867,773
Bart Jan Cornelissen
Chief Financial Officer
Total Cash $495,120 Equity $3,174,727 Other $61,164 $3,731,011
For its 2024 fiscal year, XENCOR INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Bassil I. Dahiyat Ph.D. CEO Pay $6,811,829 Median Employee Pay $270,292 CEO Pay Ratio 25:1
For its 2024 fiscal year, XENCOR INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
A. Bruce Montgomery Total Cash $372,899
Barbara Klencke Total Cash $324,399
Dagmar Rosa-Bjorkeson Total Cash $339,899
Ellen G. Feigal Total Cash $338,399
Kevin C. Gorman Total Cash $332,899
Kurt A. Gustafson Total Cash $336,899
Richard J. Ranieri Total Cash $340,399
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.